BRAF and melanoma: At present, the decision as to whether to first employ targeted- or immune checkpoint therapy in patients with BRAF positive melanoma is reached after careful consideration of the overall disease burden, LDH levels, the presence of central nervous system metastases and clinician/individual patient preference.